Alexander M. Litvintchouk
Research Subjects
Alexander M. Litvintchouk has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- David Wu
Johnson & Johnson Innovative Medicine United States Horsham Pennsylvania USA
2 shared publications - Emily Goddard
Adelphi Real World, Bollington, UK
2 shared publications - Sophie Barlow
Adelphi Real World, Bollington, UK
2 shared publications - Aaron Keal
Adelphi Real World Bollington UK
1 shared publication - James Hetherington
Adelphi Real World
1 shared publication - James Lucas
Adelphi Real World
1 shared publication
Latest Publications
- Open Access
- 7 December 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (2) , 517-528
Patient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients: Results From Real‐World Clinical Practices in Five European Countries (PROSPECT Study)
Background: Categorisation of psoriasis (PsO) disease severity in patients varies, although body surface area (BSA) affected is commonly used (< 3% ‘mild’, 3%–10% ‘moderate’ and > 10% ‘severe’). While moderate‐severe PsO has been well‐studied, more limited information regarding mild‐to‐moderate PsO is available. Objectives: To assess diagnosis, treatment patterns and disease progression for patients diagnosed with mild‐to‐moderate PsO. Methods: Data were drawn from the Adelphi Real World PsO Disease Specific Programme, a cross‐sectional survey with retrospective data collection from dermatologists and their consulting adult PsO patients in France, Germany, Italy, Spain and the United Kingdom, conducted December 2021 to March 2022. Dermatologists reported on patient demographics and clinical characteristics at survey, diagnosis and treatment initiation. Patients self‐reported the impact of PsO on their quality of life. Results: Overall, 209 dermatologists provided data for 875 patients, with 356 (40.7%) providing self‐reported data. At initial presentation, 35.3% of patients were diagnosed with mild PsO, despite 79.7% of these patients having a BSA of 3%–10%. Further, 64.7% of patients were diagnosed with moderate PsO, although 62.8% had a BSA > 10%. Between diagnosis and current treatment initiation, patients diagnosed with mild PsO showed greater deterioration than those diagnosed with moderate PsO (mean relative BSA increase of 113.2 ± 307.2% compared to 17.7 ± 93.6%; p < 0.001). Most patients received topical therapy and/or phototherapy at diagnosis (mild: 94.9%, moderate: 85.5%; p < 0.001). Those diagnosed with moderate PsO were more likely to receive systemic treatments at diagnosis ( p < 0.001) and biologics at diagnosis and time of survey ( p = 0.029 and p < 0.001, respectively). Patients diagnosed with moderate PsO showed greater quality‐of‐life impact in the DLQI ( p = 0.006) and WPAI ( p = 0.002 and p = 0.006, respectively). Conclusions: Dermatologists may underestimate severity and treatment requirements in patients diagnosed with mild‐moderate PsO. Further research into PsO underdiagnosis and advanced treatment use in cases of mild PsO may provide better optimised treatment strategies.
- 7 December 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (2) , 517-528
Open AccessPatient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients: Results From Real‐World Clinical Practices in Five European Countries (PROSPECT Study)
Background: Categorisation of psoriasis (PsO) disease severity in patients varies, although body surface area (BSA) affected is commonly used (< 3% ‘mild’, 3%–10% ‘moderate’ and > 10% ‘severe’). While moderate‐severe PsO has been well‐studied, more limited information regarding mild‐to‐moderate PsO is available. Objectives: To assess diagnosis, treatment patterns and disease progression for patients diagnosed with mild‐to‐moderate PsO. Methods: Data were drawn from the Adelphi Real World PsO Disease Specific Programme, a cross‐sectional survey with retrospective data collection from dermatologists and their consulting adult PsO patients in France, Germany, Italy, Spain and the United Kingdom, conducted December 2021 to March 2022. Dermatologists reported on patient demographics and clinical characteristics at survey, diagnosis and treatment initiation. Patients self‐reported the impact of PsO on their quality of life. Results: Overall, 209 dermatologists provided data for 875 patients, with 356 (40.7%) providing self‐reported data. At initial presentation, 35.3% of patients were diagnosed with mild PsO, despite 79.7% of these patients having a BSA of 3%–10%. Further, 64.7% of patients were diagnosed with moderate PsO, although 62.8% had a BSA > 10%. Between diagnosis and current treatment initiation, patients diagnosed with mild PsO showed greater deterioration than those diagnosed with moderate PsO (mean relative BSA increase of 113.2 ± 307.2% compared to 17.7 ± 93.6%; p < 0.001). Most patients received topical therapy and/or phototherapy at diagnosis (mild: 94.9%, moderate: 85.5%; p < 0.001). Those diagnosed with moderate PsO were more likely to receive systemic treatments at diagnosis ( p < 0.001) and biologics at diagnosis and time of survey ( p = 0.029 and p < 0.001, respectively). Patients diagnosed with moderate PsO showed greater quality‐of‐life impact in the DLQI ( p = 0.006) and WPAI ( p = 0.002 and p = 0.006, respectively). Conclusions: Dermatologists may underestimate severity and treatment requirements in patients diagnosed with mild‐moderate PsO. Further research into PsO underdiagnosis and advanced treatment use in cases of mild PsO may provide better optimised treatment strategies.
- Open Access
- 17 February 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (3) , 663-680
Patient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study)
Introduction Psoriasis (PsO) is a common dermatological condition. Psoriasis severity is commonly characterized by percentage body surface area (BSA) affected, with < 3% BSA considered mild disease and 3–10% moderate disease. Treatment options for and knowledge of clinical practice patterns in patients with mild PsO are limited. Here, we use real-world data to characterize patients diagnosed with mild and moderate PsO and their clinical management. Methods Data were derived from the Adelphi Real World PsO Disease Specific Programme™, a cross-sectional survey of dermatologists and adult patients with PsO in the USA, between December 2021 and March 2022. Dermatologists reported demographic and clinical details. Patients reported treatment satisfaction and quality of life using patient-reported outcome measures. Patients were stratified by physician-reported severity at diagnosis (mild/moderate) and compared using bivariate analyses. Results Out of 389 patients, 18.5% were diagnosed with mild PsO. The majority were female, white, and employed. Patients diagnosed with moderate PsO had higher body mass index (p = 0.002) and longer disease duration (p = 0.041). Only 22.0% of patients diagnosed with mild PsO had BSA < 3% at diagnosis, and 48.1% of patients diagnosed as moderate PsO had BSA < 10%. BSA improvement following initiation of current treatment was higher among patients diagnosed with moderate PsO (p < 0.001). Those diagnosed with moderate PsO more commonly had involvement of the elbows (p = 0.003), legs (p = 0.002), knees (p < 0.001), soles (p = 0.035), and back (p = 0.004) at diagnosis. Cracked skin, redness, and tender skin (p < 0.001 for all) were more common among those diagnosed with moderate PsO. Both groups mostly received topical agents; however, those diagnosed with moderate PsO more commonly received systemic (p < 0.001) or biologic (p = 0.002) treatment. Patients diagnosed with moderate PsO had lower EQ-5D-5L (p = 0.014) and treatment satisfaction (p = 0.007) scores. Conclusion These findings suggest that physicians routinely underestimate PsO severity, resulting in possible undertreatment, suboptimal outcomes, and quality-of-life impairments for patients with milder severity PsO.
- 17 February 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (3) , 663-680
Open AccessPatient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study)
Introduction Psoriasis (PsO) is a common dermatological condition. Psoriasis severity is commonly characterized by percentage body surface area (BSA) affected, with < 3% BSA considered mild disease and 3–10% moderate disease. Treatment options for and knowledge of clinical practice patterns in patients with mild PsO are limited. Here, we use real-world data to characterize patients diagnosed with mild and moderate PsO and their clinical management. Methods Data were derived from the Adelphi Real World PsO Disease Specific Programme™, a cross-sectional survey of dermatologists and adult patients with PsO in the USA, between December 2021 and March 2022. Dermatologists reported demographic and clinical details. Patients reported treatment satisfaction and quality of life using patient-reported outcome measures. Patients were stratified by physician-reported severity at diagnosis (mild/moderate) and compared using bivariate analyses. Results Out of 389 patients, 18.5% were diagnosed with mild PsO. The majority were female, white, and employed. Patients diagnosed with moderate PsO had higher body mass index (p = 0.002) and longer disease duration (p = 0.041). Only 22.0% of patients diagnosed with mild PsO had BSA < 3% at diagnosis, and 48.1% of patients diagnosed as moderate PsO had BSA < 10%. BSA improvement following initiation of current treatment was higher among patients diagnosed with moderate PsO (p < 0.001). Those diagnosed with moderate PsO more commonly had involvement of the elbows (p = 0.003), legs (p = 0.002), knees (p < 0.001), soles (p = 0.035), and back (p = 0.004) at diagnosis. Cracked skin, redness, and tender skin (p < 0.001 for all) were more common among those diagnosed with moderate PsO. Both groups mostly received topical agents; however, those diagnosed with moderate PsO more commonly received systemic (p < 0.001) or biologic (p = 0.002) treatment. Patients diagnosed with moderate PsO had lower EQ-5D-5L (p = 0.014) and treatment satisfaction (p = 0.007) scores. Conclusion These findings suggest that physicians routinely underestimate PsO severity, resulting in possible undertreatment, suboptimal outcomes, and quality-of-life impairments for patients with milder severity PsO.